Stay updated on REOLYSIN in KRAS Mutant CRC Clinical Trial
Sign up to get notified when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.
Latest updates to the REOLYSIN in KRAS Mutant CRC Clinical Trial page
- Check3 days agoChange DetectedRevision from v3.3.3 to v3.3.4 appears as a minor administrative update in the page footer; no study content or actions are affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded a new Locations section with New York as a site; removed the New York Locations label and the HHS Vulnerability Disclosure link in this revision.SummaryDifference0.2%
- Check53 days agoChange DetectedFooter now shows Revision: v3.3.2, and Revision: v3.2.0 has been removed.SummaryDifference0.1%
- Check60 days agoChange DetectedRemoved a broad notice about potential data delays due to a lapse in government funding, including references to cc.nih.gov and opm.gov for status updates. This notice framed site operations rather than the trial details themselves.SummaryDifference0.4%
- Check74 days agoChange DetectedNo significant additions or deletions were detected on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check96 days agoChange DetectedUpdate includes a funding-related operations notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference4%
Stay in the know with updates to REOLYSIN in KRAS Mutant CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.